임상시험 트래커

추적 기업 30곳의 임상 6,982건 (국내 전체 이력 · 글로벌 진행 중). 출처: ClinicalTrials.gov

34건 표시

2상완료· Age-Related Macular Degeneration
A Study to Evaluate the Usability of the SB11 PFS in Trial Participants With Wet AMD, Macular Oedema Secondary to RVO, or mCNV
리드: 삼성바이오에피스
상세 →NCT07550504
1상모집 중· Advanced Solid Tumors
A Trial to Investigate the Safety of E303 in Participants With Advanced Refractory Solid Tumors
리드: 삼성바이오에피스
상세 →NCT07524348
3상모집 중단 (진행 중)· Non-small Cell Lung Cancer Stage IV
A Study to Compare the Efficacy, Safety, Pharmacokinetics, and Immunogenicity Between SB27 and Keytruda in Subjects With Metastatic Non-squamous Non-small Cell Lung Cancer
리드: 삼성바이오에피스
상세 →NCT06348199
1상모집 중단 (진행 중)· Non-small Cell Lung Cancer Stage II
A Study to Compare the Pharmacokinetics, Efficacy, Safety, and Immunogenicity of Pembrolizumab (SB27, EU Sourced Keytruda, and US Sourced Keytruda) in Subjects With Stage II-IIIA NSCLC Following Complete Resection and Adjuvant Platinum-based Chemotherapy
리드: 삼성바이오에피스
상세 →NCT06268613
2상완료· Neovascular Age-related Macular Degeneration
A Study to Evaluate the Usability of the SB11 PFS in Subjects With Wet AMD or Macular Oedema Secondary to RVO
리드: 삼성바이오에피스
상세 →NCT06176963
4상완료· Plaque Psoriasis
Pharmacokinetics, Efficacy, Safety, and Immunogenicity of SB5 Versus Humira in Subjects With Moderate to Severe Chronic Plaque Psoriasis
리드: 삼성바이오에피스
상세 →NCT05510063
4상상태 미확인· Breast Cancer
Neoadjuvant Ontruzant (SB3) in Patients With HER2-positive Early Breast Cancer: An Open-Label (NeoON)
협력: 삼성바이오에피스
상세 →NCT05036005
3상완료· Psoriasis
A Study to Compare SB17 (Proposed Ustekinumab Biosimilar) to Stelara® in Subject With Moderate to Severe Plaque Psoriasis
리드: 삼성바이오에피스
상세 →NCT04967508
1상완료· Healthy
A Study to Compare SB17 (Proposed Ustekinumab Biosimilar) to European Union (EU) Sourced Stelara and United States of America (US) Sourced Stelara in Healthy Subjects
리드: 삼성바이오에피스
상세 →NCT04772274
3상완료· Postmenopausal Osteoporosis
A Study to Compare SB16 (Proposed Denosumab Biosimilar) to Prolia® in Postmenopausal Women With Osteoporosis
리드: 삼성바이오에피스
상세 →NCT04664959
1상완료· Healthy
Pharmacokinetics, Pharmacodynamics, Safety, Tolerability, and Immunogenicity Study of SB16 in Healthy Male Subjects
리드: 삼성바이오에피스
상세 →NCT04621318
1상완료· Healthy
Pharmacokinetics, Safety, Tolerability, and Immunogenicity of Two Formulations of SB5 in Healthy Male Subjects
리드: 삼성바이오에피스
상세 →NCT04514796
3상완료· Neovascular Age-related Macular Degeneration
A Study to Compare SB15 (Proposed Aflibercept Biosimilar) to Eylea in Subjects With Neovascular Age-related Macular Degeneration (AMD)
리드: 삼성바이오에피스
상세 →NCT04450329
3상완료· Paroxysmal Nocturnal Hemoglobinuria
A Study to Compare SB12 (Proposed Eculizumab Biosimilar) to Soliris in Subjects With Paroxysmal Nocturnal Haemoglobinuria
리드: 삼성바이오에피스
상세 →NCT04058158
4상상태 미확인· Rheumatoid Arthritis
Targeted Treatment Early With Etanercept + Methotrexate vs.T2T Care for DMARD-naïve Early RA Patients Based on naïve T-cell Stratification
협력: 삼성바이오에피스
상세 →NCT03813771
1상완료· Healthy
Pharmacokinetic, Safety, Tolerability, Immunogenicity, and Pharmacodynamic Study of SB12 in Healthy Subjects
리드: 삼성바이오에피스
상세 →NCT03722329
1상완료· Healthy Volunteers
A Phase I Study of SB26 in Healthy Volunteers
리드: 삼성바이오에피스
상세 →NCT03630627
3상완료· Age-Related Macular Degeneration
A Study to Compare SB11 (Proposed Ranibizumab Biosimilar) to Lucentis in Subjects With Neovascular Age-related Macular Degeneration (AMD)
리드: 삼성바이오에피스
상세 →NCT03150589
단계 미표기완료· Rheumatoid Arthritis
Observational Study to Evaluate the Real-Life Effectiveness of Benepali Following Transition From Enbrel
협력: 삼성바이오에피스
상세 →NCT03100734
2상완료· Rheumatoid Arthritis
An Multicentre Clinical Study to Evaluate the Usability and Safety of the Autoinjector and Pre-filled Syringe of SB4 in Subjects With Rheumatoid Arthritis
리드: 삼성바이오에피스
상세 →NCT03193957
1상완료· Healthy
Pharmacokinetics, Safety, and Tolerability Study of the Autoinjector and Pre-filled Syringe of SB4 in Healthy Male Subjects
리드: 삼성바이오에피스
상세 →NCT03193203
3상완료· Lung Cancer
A Study Comparing SB8 and Avastin® in Patients With Advanced Non-squamous Non-small Cell Lung Cancer
리드: 삼성바이오에피스
상세 →NCT02754882
단계 미표기조기 종료· Breast Neoplasms
A Long-term Follow-up Study for Cardiac Safety in the Patients With HER2 (+) Breast Cancer Who Have Completed the SB3-G31-BC
리드: 삼성바이오에피스
상세 →NCT02771795
2상완료· Rheumatoid Arthritis
An Multicentre Clinical Study to Evaluate the Usability and Safety of the Pre-filled Pen and Pre-filled Syringe of SB5 in Subjects With Rheumatoid Arthritis
리드: 삼성바이오에피스
상세 →NCT02565810
1상완료· Healthy
Pharmacokinetics, Safety, and Tolerability Study of the Pen and PFS of SB5 in Healthy Subjects
리드: 삼성바이오에피스
상세 →NCT02326233
1상완료· Healthy
Pharmacokinetic, Safety, Tolerability, and Immunogenicity Study of SB8 in Healthy Male Subjects
리드: 삼성바이오에피스
상세 →NCT02453672
1상완료· Healthy
Pharmacokinetic, Safety, Tolerability and Immunogenicity Study of SB5 in Healthy Subjects
리드: 삼성바이오에피스
상세 →NCT02144714
3상완료· Rheumatoid Arthritis
A Study Comparing SB5 to Humira® in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy
리드: 삼성바이오에피스
상세 →NCT02167139
3상완료· HER2 Positive Early or Locally Advanced Breast Cancer
A Study to Compare the Effect of SB3 and Herceptin® in Women With HER2 Positive Breast Cancer
리드: 삼성바이오에피스
상세 →NCT02149524
1상완료· Healthy
Pharmacokinetic, Safety, Tolerability and Immunogenicity Study of SB3 in Healthy Male Subjects
리드: 삼성바이오에피스
상세 →NCT02075073
3상완료· Rheumatoid Arthritis
A Study Comparing SB2 to Remicade® in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy
리드: 삼성바이오에피스
상세 →NCT01936181
1상완료· Healthy
Pharmacokinetic, Safety, Tolerability and Immunogenicity Study of SB2 in Healthy Subjects
리드: 삼성바이오에피스
상세 →NCT01922336
3상완료· Rheumatoid Arthritis
A Study Comparing SB4 to Enbrel® in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy
리드: 삼성바이오에피스
상세 →NCT01895309
1상완료· Healthy
Pharmacokinetic, Safety, Tolerability and Immunogenicity Study of SB4 in Healthy Male Subjects
리드: 삼성바이오에피스
상세 →NCT01865552

BioPulse가 제공하는 정보는 공개된 자료를 요약·정리한 것으로, 투자 조언이나 의료 조언이 아닙니다. 임상 데이터·규제 일정·공시 내용은 반드시 원문을 직접 확인하시기 바랍니다.